XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney ...

XORTX Therapeutics Inc.: XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therape ...
Medindia

Predicting Kidney Failure Before It Starts: New Blood Test Shows Promise

Early detection of kidney disease is now possible with a simple blood test, as a protein-based risk score can predict kidney ...

Blood test predicts kidney failure risk to Black Americans years before onset

A new blood test can identify which individuals of African ancestry carrying high-risk APOL1 gene variants are most likely to ...

World Liver Day: Experts warn liver disease is the ‘fourth major complication’ of diabetes

Fatty liver linked to diabetes is emerging as a silent but serious complication, progressing without symptoms and affecting ...

2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term

Vertex Pharmaceuticals (NASDAQ: VRTX) and Mirum Pharmaceuticals (NASDAQ: MIRM) are two biotech stocks that share the same ...
Taipei Times

Boy with transplants from parents returns to school

A boy who received a partial liver transplant from his mother and a kidney transplant from his father within a year has ...
Renal & Urology News

Recognizing Potential Overlap of IgG4-RD, AAV Is Key to Optimal Treatment

The patient in the current case report showed manifestations of both AAV and IgG4-RD; his improvement linked to steroid/cyclophosphamide treatment underscores the need for integrated diagnosis and ...